IVA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IV

Mkt Cap

$695.9M

Volume

4.76M

Loading chart

IV

IVAInventiva S.A. American Depository Shares

IVA

Pay with—

Available Balance0.00

IV

Mkt Cap

$694.5M

Volume

4.76M

Next Earnings

N/A

Chart Earnings News About Insider Filings

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 developmentClaret Capital Partners has invested €43m in clinical-stage biopharmaceutical company Inventiva as part of a €130m debt financing round. Inventiva is developing lanifibranor, an oral therapy for MASH (metabolic dysfunction-associated steatohepatitis), with Phase 3 trial results expected in Q4 2026. The financing, alongside BlackRock-managed funds, aims to support the company through key clinical and regulatory milestones.GlobeNewswire Inc. · Jun 16, 2026

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt FinancingInventiva completed repayment of €62 million in EIB loans and repurchased EIB warrants for €50 million. The company simultaneously issued €75 million in new debt financing (€35 million convertible bonds and €40 million amortized bonds) from BlackRock and Claret Capital Partners, following a successful €120 million equity offering of ADSs at $4.40 per share.GlobeNewswire Inc. · Jun 12, 2026

Combined General Meeting of June 30, 2026 - Availability of the Preparatory DocumentsInventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, announced the availability of preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The meeting agenda includes a 39th resolution related to a master agreement with the European Investment Bank (EIB) for full repayment of existing loans and buyback of warrants for €50 million, with issuance of new warrants on standard terms. The company is currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.GlobeNewswire Inc. · Jun 9, 2026

Information relative au nombre total de droits de vote et d’actions composant le capital social au 22 mai 2026Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.GlobeNewswire Inc. · Jun 9, 2026

Assemblée Générale Mixte du 30 juin 2026 - Modalités de mise à disposition des documents préparatoiresInventiva announced the arrangements for its Mixed General Assembly scheduled for June 30, 2026 in Paris. The agenda includes a 39th resolution regarding a master agreement with the European Investment Bank (EIB) signed on June 1, 2026, which involves full repayment of existing EIB loans and repurchase of warrant subscription rights (BSA) for €50 million. The company also adjusted caps for resolutions related to free share allocations and warrant issuances based on recent board decisions.GlobeNewswire Inc. · Jun 9, 2026

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and disclosed preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights as of May 22, 2026.GlobeNewswire Inc. · Jun 9, 2026

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext ParisInventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced a temporary trading halt on Euronext Paris on June 2, 2026, ahead of a proposed financing transaction. Trading was expected to resume at approximately 3:30 p.m. CEST, coinciding with the opening of Nasdaq trading. The company reported Q1 2026 cash and equivalents of €75.0 million plus €121.5 million in short-term deposits.GlobeNewswire Inc. · Jun 2, 2026

Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext ParisInventiva announced on June 2, 2026, that trading of its ordinary shares on Euronext Paris will be temporarily suspended starting at market open (9:00 CEST) pending disclosure of a financing operation. Trading is expected to resume later that day around 15:30 CEST, coinciding with potential trading resumption on Nasdaq. The company is a clinical-stage biopharmaceutical firm developing lanifibranor, a pan-PPAR agonist, for treating MASH (metabolic dysfunction-associated steatohepatitis).GlobeNewswire Inc. · Jun 2, 2026

Inventiva Reports 2026 First Quarter Financial Information¹Inventiva, a clinical-stage biopharmaceutical company, reported Q1 2026 financial results showing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million, down from €99.3 million and €131.6 million respectively at year-end 2025. The company estimates its current resources will fund operations until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company generated no revenues in Q1 2026 and expects NATiV3 Phase 3 trial topline results in Q4 2026.GlobeNewswire Inc. · May 26, 2026

Inventiva publie ses informations financières du premier trimestre 2026¹Inventiva, a clinical-stage biopharmaceutical company, reported cash and equivalents of €75 million and short-term deposits of €121.5 million as of March 31, 2026. The company estimates its liquidity will fund operations until mid-Q1 2027, or potentially mid-Q3 2027 if warrant exercises from its structured financing reach €116 million. No revenue was recorded in Q1 2026. Key milestone: NATiV3 Phase 3 trial results for lanifibranor (MASH treatment) are expected in Q4 2026.GlobeNewswire Inc. · May 26, 2026

to start trading

IV

IVAInventiva S.A. American Depository Shares

IVA

Pay with—

Available Balance0.00

Your PositionYou don't own any IVA yet.

Related Tickers

Earnings